A significant advancement in the field of multiple sclerosis (MS) treatment! The research led by Patrick Vermersch, Cristina Granziera and Gavin Giovannoni surrounding the CD40–CD40L costimulatory pathway has paved the way for a potential game-changer - Frexalimab, a second-generation anti-CD40L monoclonal antibody.
The CD40–CD40L pathway plays a crucial role in regulating both adaptive and innate immune responses and has long been implicated in the pathogenesis of multiple sclerosis. With its intricate involvement in the disease process, targeting this pathway has become a promising avenue for developing effective treatments. Frexalimab represents a new frontier in MS therapeutics. As a second-generation anti-CD40L monoclonal antibody, it holds the potential to provide novel and improved solutions for individuals affected by this complex neurological disorder.
Multiple sclerosis manifests in two principal forms: relapsing and progressive. Relapsing MS is characterized by recurrent attacks, initially with remissions, but can lead to lasting disability over time. On the other hand, progressive MS involves continuous worsening. Understanding these distinct forms has been essential in tailoring effective treatment approaches. Relapsing multiple sclerosis primarily involves the adaptive immune system, orchestrated by circulating B lymphocytes that traffic into the central nervous system. In contrast, progression is mediated by both the adaptive and innate immune systems. The editorial accompanying this research by Stephen L. Hauser emphasizes the significance of addressing these different mechanisms in the treatment of two forms of MS. https://www.nejm.org/doi/full/10.1056/NEJMe2314434
The future of MS treatment is on the horizon, and we are eager to witness the positive changes that may result from this innovative research.
Read the full original article here: https://www.nejm.org/doi/pdf/10.1056/NEJMoa2309439?articleTools=true
